ProQR (PRQR)
2.07
-0.02 (0.96%)
Upcoming Events
Latest Headlines
ProQR to Participate in Upcoming Investor Conferences in September 2026
September 2, 2026 8:00 AM - StreetInsider
BofA Securities Starts ProQR Therapeutics N.V. (PRQR) at Buy
August 20, 2026 7:15 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on ProQR Therapeutics N.V. (PRQR)
August 17, 2026 6:52 AM - StreetInsider
Form 6-K ProQR Therapeutics N.V. For: Jun 30
August 13, 2026 7:01 AM - SEC Filing
Form 6-K ProQR Therapeutics N.V. For: Aug 13
August 13, 2026 7:00 AM - SEC Filing
ProQR Announces Second Quarter 2026 Operating and Financial Results
August 13, 2026 7:00 AM - StreetInsider
Form 4 ProQR Therapeutics N.V. For: Jul 31 Filed by: de Boer Daniel Anton
August 3, 2026 4:01 PM - SEC Filing
Form SCHEDULE 13D/A ProQR Therapeutics N.V. Filed by: VAN HERK INVESTMENTS B.V.
July 29, 2026 4:04 PM - SEC Filing
Form SCHEDULE 13G ProQR Therapeutics N.V. Filed by: Aberdeen Group plc
July 29, 2026 9:48 AM - SEC Filing
Form SCHEDULE 13G/A ProQR Therapeutics N.V. Filed by: ELI LILLY & Co
July 24, 2026 4:31 PM - SEC Filing
Form 4 ProQR Therapeutics N.V. For: Jul 17 Filed by: Filius Bart
July 21, 2026 8:00 AM - SEC Filing
Form EFFECT ProQR Therapeutics N.V.
July 16, 2026 6:05 AM - SEC Filing
Form 424B5 ProQR Therapeutics N.V.
July 15, 2026 4:30 PM - SEC Filing
Form SCHEDULE 13G/A ProQR Therapeutics N.V. Filed by: Privium Fund Management B.V.
July 15, 2026 11:55 AM - SEC Filing
Form 4 ProQR Therapeutics N.V. For: Jul 09 Filed by: de Boer Daniel Anton
July 13, 2026 8:00 AM - SEC Filing
Form 4 ProQR Therapeutics N.V. For: Jul 07 Filed by: de Boer Daniel Anton
July 8, 2026 2:55 PM - SEC Filing
Form F-3 ProQR Therapeutics N.V.
July 6, 2026 4:11 PM - SEC Filing
Form SCHEDULE 13D/A ProQR Therapeutics N.V. Filed by: VAN HERK INVESTMENTS B.V.
June 30, 2026 5:23 PM - SEC Filing
Form 4/A ProQR Therapeutics N.V. For: Jun 02 Filed by: Hinsch Gylvin Lykke
June 30, 2026 4:02 PM - SEC Filing
Form 4 ProQR Therapeutics N.V. For: Jun 26 Filed by: Filius Bart
June 30, 2026 4:01 PM - SEC Filing
Form 424B5 ProQR Therapeutics N.V.
June 26, 2026 6:03 AM - SEC Filing
Form 6-K ProQR Therapeutics N.V. For: Jun 26
June 26, 2026 6:03 AM - SEC Filing
ProQR prices $50M share offering with Eli Lilly joining as buyer
June 25, 2026 6:35 AM - StreetInsider
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
June 25, 2026 6:35 AM - StreetInsider
Form 6-K ProQR Therapeutics N.V. For: Jun 25
June 25, 2026 6:31 AM - SEC Filing
ProQR reports positive Phase 1 data for RNA editing drug AX-0810
June 25, 2026 6:25 AM - StreetInsider
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
June 25, 2026 6:25 AM - StreetInsider
Full Article List
